Quick Answer
Outset Medical, Inc. reported Total Revenue of $119.48 million for fiscal year 2025.
Outset Medical, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $119.48M +5.1% |
$113.69M -12.8% |
$130.38M +13.0% |
$115.38M +12.4% |
$102.60M +105.5% |
$49.94M +231.2% |
| Revenue (ASC 606) | $119.48M +5.1% |
$113.69M -12.8% |
$130.38M +13.0% |
$115.38M +12.4% |
$102.60M +105.5% |
$49.94M +231.2% |
| Net Income | -$81.65M +36.2% |
-$127.98M +25.9% |
-$172.80M -6.0% |
-$162.96M -23.5% |
-$131.94M -8.6% |
-$121.49M -77.9% |
| Diluted EPS | -$5.37 +85.5% |
-$36.96 +29.3% |
-$52.28 -1446.7% |
-$3.38 -17.0% |
-$2.89 +40.4% |
-$4.85 |
| Total Assets | $264.50M -4.1% |
$275.80M -12.1% |
$313.80M -21.6% |
$400.12M -13.7% |
$463.46M +14.8% |
$403.83M +357.0% |
| Cash and Equivalents | $35.01M -71.8% |
$124.01M +81.0% |
$68.51M -6.4% |
$73.22M -59.8% |
$182.35M -38.2% |
$294.97M +698.8% |
| Long-Term Debt | $96.24M -51.2% |
$197.38M +51.7% |
$130.11M +35.1% |
$96.34M +223.7% |
$29.76M +0.3% |
$29.67M +37.6% |
| Stockholders Equity | $126.95M +373.4% |
$26.82M -78.2% |
$122.89M -50.0% |
$245.99M -34.2% |
$374.08M +13.8% |
$328.61M +188.3% |
| R&D Expense | $21.23M -44.7% |
$38.40M -33.0% |
$57.31M +17.3% |
$48.85M +33.0% |
$36.74M +27.4% |
$28.85M +23.7% |
| Operating Income | -$66.71M +41.2% |
-$113.38M +33.2% |
-$169.77M -5.4% |
-$161.02M -23.4% |
-$130.52M -11.1% |
-$117.47M -67.1% |
| Gross Profit | $46.75M +21.2% |
$38.56M +33.0% |
$29.00M +62.6% |
$17.83M +134.4% |
$7.61M +158.4% |
-$13.04M +26.8% |
| Shares Outstanding | 18.17M +414.7% |
3.53M -93.0% |
50.32M +3.8% |
48.47M +2.6% |
47.24M +10.6% |
42.72M +4533.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $29.43M | +2.7% | -6.3% |
| Revenue (ASC 606) | September 30, 2025 | $29.43M | +2.7% | -6.3% |
| Net Income | September 30, 2025 | -$17.84M | +36.2% | +3.8% |
| Diluted EPS | September 30, 2025 | -$1.00 | +87.5% | +3.8% |
| Total Assets | September 30, 2025 | $277.25M | -5.3% | -4.0% |
| Cash and Equivalents | September 30, 2025 | $36.44M | +9.5% | -7.9% |
| Long-Term Debt | September 30, 2025 | $95.52M | -51.6% | +0.7% |
| Stockholders Equity | September 30, 2025 | $142.37M | +197.7% | -8.0% |
| R&D Expense | September 30, 2025 | $5.38M | -33.9% | +1.6% |
| Operating Income | September 30, 2025 | -$15.81M | +33.7% | +6.2% |
| Gross Profit | September 30, 2025 | $11.59M | +18.0% | -2.3% |
| Shares Outstanding | September 30, 2025 | 17.81M | -66.1% | +0.2% |
- Outset Medical, Inc. reported Total Revenue of $119.48 million for fiscal year 2025.
- Outset Medical, Inc. showed an increase of +5.1% in Total Revenue compared to the prior fiscal year.
- Outset Medical, Inc. reported Revenue (ASC 606) of $119.48 million for fiscal year 2025.
- Outset Medical, Inc. showed an increase of +5.1% in Revenue (ASC 606) compared to the prior fiscal year.
- Outset Medical, Inc. reported Net Income of -$81.65 million for fiscal year 2025.
- Outset Medical, Inc. showed an increase of +36.2% in Net Income compared to the prior fiscal year.
- Outset Medical, Inc. reported Diluted EPS of $5.37 per share (loss) for fiscal year 2025.
- Outset Medical, Inc. showed an increase of +85.5% in Diluted EPS compared to the prior fiscal year.
- Outset Medical, Inc. reported Total Assets of $264.50 million for fiscal year 2025.
- Outset Medical, Inc. showed a decrease of -4.1% in Total Assets compared to the prior fiscal year.
- Outset Medical, Inc. reported Cash and Equivalents of $35.01 million for fiscal year 2025.
- Outset Medical, Inc. showed a decrease of -71.8% in Cash and Equivalents compared to the prior fiscal year.
- Outset Medical, Inc. reported Long-Term Debt of $96.24 million for fiscal year 2025.
- Outset Medical, Inc. showed a decrease of -51.2% in Long-Term Debt compared to the prior fiscal year.
- Outset Medical, Inc. reported Stockholders Equity of $126.95 million for fiscal year 2025.
- Outset Medical, Inc. showed an increase of +373.4% in Stockholders Equity compared to the prior fiscal year.
- Outset Medical, Inc. reported R&D Expense of $21.23 million for fiscal year 2025.
- Outset Medical, Inc. showed a decrease of -44.7% in R&D Expense compared to the prior fiscal year.
- Outset Medical, Inc. reported Operating Income of -$66.71 million for fiscal year 2025.
- Outset Medical, Inc. showed an increase of +41.2% in Operating Income compared to the prior fiscal year.
- Outset Medical, Inc. reported Gross Profit of $46.75 million for fiscal year 2025.
- Outset Medical, Inc. showed an increase of +21.2% in Gross Profit compared to the prior fiscal year.
- Outset Medical, Inc. reported Shares Outstanding of 18.17 million shares for fiscal year 2025.
- Outset Medical, Inc. showed an increase of +414.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: